<DOC>
	<DOC>NCT00544154</DOC>
	<brief_summary>The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.</brief_summary>
	<brief_title>Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>male/female, 1875 years old, inclusive diagnosis of adultonset RA had active disease had received methotrexate on a stable dose of folic acid contraindication for methotrexate or antiTNF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>CDP870</keyword>
	<keyword>Certolizumab pegol</keyword>
</DOC>